Charles Schwab Investment Management Inc. Raises Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Charles Schwab Investment Management Inc. boosted its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 2.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 319,030 shares of the biotechnology company's stock after buying an additional 7,723 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.68% of United Therapeutics worth $70,152,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of UTHR. GAMMA Investing LLC bought a new position in United Therapeutics during the fourth quarter worth $43,000. C M Bidwell & Associates Ltd. bought a new position in shares of United Therapeutics during the 3rd quarter worth about $91,000. Blue Trust Inc. grew its stake in shares of United Therapeutics by 10.0% in the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company's stock valued at $114,000 after buying an additional 46 shares during the period. CWM LLC increased its position in United Therapeutics by 45.7% in the 4th quarter. CWM LLC now owns 670 shares of the biotechnology company's stock valued at $147,000 after buying an additional 210 shares in the last quarter. Finally, Synovus Financial Corp acquired a new position in United Therapeutics during the 3rd quarter worth approximately $203,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on UTHR. Leerink Partnrs restated an "outperform" rating on shares of United Therapeutics in a research note on Monday, February 5th. The Goldman Sachs Group lifted their target price on United Therapeutics from $218.00 to $240.00 and gave the stock a "neutral" rating in a research note on Friday, May 3rd. SVB Leerink assumed coverage on shares of United Therapeutics in a research report on Monday, February 5th. They set an "outperform" rating and a $330.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and issued a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, May 2nd. Finally, Wedbush reissued an "outperform" rating and set a $308.00 target price on shares of United Therapeutics in a research report on Thursday, February 22nd. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $308.78.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR traded up $2.91 during trading on Wednesday, hitting $272.69. 370,399 shares of the company were exchanged, compared to its average volume of 462,713. United Therapeutics Co. has a 52-week low of $204.44 and a 52-week high of $275.00. The stock has a 50 day moving average of $242.74 and a 200 day moving average of $231.62. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The company has a market cap of $12.10 billion, a PE ratio of 12.89 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The company had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. During the same period in the previous year, the company posted $4.86 EPS. The firm's revenue for the quarter was up 33.7% compared to the same quarter last year. As a group, equities research analysts predict that United Therapeutics Co. will post 24.2 EPS for the current year.

Insider Transactions at United Therapeutics

In other news, Director Christopher Causey sold 2,240 shares of the company's stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $259.91, for a total value of $582,198.40. Following the transaction, the director now owns 4,185 shares of the company's stock, valued at $1,087,723.35. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the business's stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $215.31, for a total value of $1,291,860.00. Following the completion of the transaction, the executive vice president now owns 36,599 shares of the company's stock, valued at approximately $7,880,130.69. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Christopher Causey sold 2,240 shares of the stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $259.91, for a total transaction of $582,198.40. Following the completion of the transaction, the director now directly owns 4,185 shares in the company, valued at approximately $1,087,723.35. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 156,140 shares of company stock valued at $37,343,022. 12.50% of the stock is currently owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.